Deals channel feed – Endpoints News

Deals channel feed

Bouncing from major setback, Summit hands out $500M cash for cancer drug — thanks to a loan from billionaire CEO

3 years ago

AbbVie puts up $40M to license a treatment from HotSpot Therapeutics

3 years ago

In search for next-gen Covid treatment, Pfizer taps tiny biotech for research deal

3 years ago

And then there were two: Janssen bows out of Horizon takeover negotiations

3 years ago

After M&A fell through, TherapeuticsMD sells hormone therapy, contraceptive ring for $140M cash plus royalties

3 years ago

In search for a 'universal T cell engager', Immunocore inks deal with Gilead-backed Gadeta

3 years ago

A fledgling biotech goes SPAC route to bankroll cancer vaccine, CAR-T and CD47

3 years ago

Sanofi and Amgen are bringing cash to cover the table stakes for the Horizon M&A game

3 years ago

Pfizer and Roivant team up again for another 'Vant', setting up anti-inflammatory showdown with Prometheus

3 years ago

Rallybio, AbCellera form new partnership around antibodies for rare disease

3 years ago

Argenx purchases $100M+ FDA priority review voucher from bluebird bio

3 years ago

BioNTech bets on difficult STING field via small molecule pact with a Polish biotech

3 years ago

Horizon Therapeutics in takeover talks with Amgen, J&J, Sanofi as potential buyers

3 years ago

Fosun Pharma considers $3.8B sale of Indian drugmaker Gland Pharma — report

3 years ago

Resilience purchases Ohio biomanufacturing site from AstraZeneca

3 years ago

Bristol Myers scraps gene therapy deal with uniQure for cardiovascular diseases

3 years ago

With ops spanning Belgium and China, Full-Life inks $245M buyout to beef up radiopharma pipeline

3 years ago

Updated: AstraZeneca jumps deeper into cell therapy 2.0 space with $320M biotech M&A

3 years ago

In new deal, AstraZeneca places small bet on 'critical but challenging' target

3 years ago

Mirati gauging sale interest of Big Pharmas — report

3 years ago

ObsEva, desperate for cash, sells rights to PhII drug in bid to extend runway, test new pregnancy candidate

3 years ago

Cyclerion board quickly nixes CEO Peter Hecht's unorthodox pitch for low cash reserves

3 years ago

After Chinese CDMO fails, Cambrex acquires ingredient manufacturer Snapdragon Chemistry

3 years ago

Updated: No Seagen here: 'Do more' means a small $1.35B purchase of Imago for Merck

3 years ago

First page Previous page 45 46 474849 50 51 Next page Last page